Interindividual variability in sensitivity to warfarin‐Nature or nurture?

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Clinical pharmacology and therapy

• Publication date

  2001-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1067/mcp.2001.117444PMID 11503010
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Contributions Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation

  2001cited by this paper
• Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

  2001cited by this paper
• Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range

  2001cited by this paper
• CYP2C9*3 allelic variant and bleeding complications.

  1999cited by this paper
• Response of vitamin K status to different intakes and sources of phylloquinone-rich foods: comparison of younger and older adults.

  1999cited by this paper
• Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

  1999cited by this paper
• Vitamin K Intake and Sensitivity to Warfarin in Patients Consuming Regular Diets

  1999cited by this paper
• Acetaminophen and other risk factors for excessive warfarin anticoagulation.

  1998cited by this paper
• Genetic association between sensitivity to warfarin and expression of CYP2C9*3.

  1997cited by this paper
• Human P450 metabolism of warfarin.

  1997cited by this paper
• Genetic analysis of the human cytochrome P450 CYP2C9 locus.

  1996cited by this paper
• Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese.

  1995cited by this paper
• The influence of age, liver size and enantiomer concentrations on warfarin requirements.

  1995cited by this paper
• Multiple dose regimens. Impact on compliance.

  1995cited by this paper
• Interactions of Warfarin with Drugs and Food

  1994cited by this paper
• Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin.

  1994cited by this paper
• Factors affecting the maintenance dose of warfarin.

  1992cited by this paper
• Aging and the Anticoagulant Response to Warfarin Therapy

  1992cited by this paper
• Geigy Scientific Tables

  1991cited by this paper
• Standardised initial warfarin treatment: evaluation of initial treatment response and maintenance dose prediction by randomised trial, and risk factors for an excessive warfarin response.

  1991cited by this paper
• Anticoagulation instability with life-threatening complication after dietary modification.

  1990cited by this paper
• Phylloquinone in plasma from elderly and young adults: factors influencing its concentration.

  1989cited by this paper
• Enteral feeds may antagonise warfarin.

  1984cited by this paper
• Myocardial infarction after diet-induced warfarin resistance.

  1984cited by this paper
• Warfarin resistance caused by broccoli.

  1983cited by this paper
• Warfarin resistance caused by broccoli.

  1983cited by this paper
• Acquired warfarin resistance and weight-reducing diet.

  1981cited by this paper
• Determinants of anticoagulant control in patients receiving warfarin.

  1977cited by this paper
• High-pressure liquid chromatographic analysis of drugs in biological fluids I. Warfarin.

  1977cited by this paper

• The impact of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin dose requirement in Saudi patients

  2025cites this paper
• The Application of Machine Learning in Warfarin Dose Precision for Diabetic Patients Treated with Statins: A Comparative Study.

  2025cites this paper
• Pharmacodynamic Modeling of Warfarin Dosing Algorithm for Cardiovascular Patients in Indonesia: A Tailored Method to Anticoagulation Therapy

  2025cites this paper
• Improved stacking ensemble learning based on feature selection to accurately predict warfarin dose

  2024cites this paper
• A Semi-Mechanistic Population Pharmacokinetic Model of Noscapine in Healthy Subjects Considering Hepatic First-Pass Extraction and CYP2C9 Genotypes

  2024cites this paper
• To stop or not to stop novel oral anticoagulants prior to performing joint interventional maneuvers? Evidence from a prospective study that the therapy can be maintained

  2024cites this paper
• Effect of the quality of anticoagulation on the risk of stroke, thrombotic events, hemorrhagic events, and death in patients with nonvalvular atrial fibrillation on acenocoumarol in Real-World Data

  2024cites this paper
• Characterizing the genetic architecture of drug response using gene-context interaction methods

  2024cites this paper
• Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines

  2023cites this paper
• Various Factors Influencing the Enantiomers of Warfarin Pharmacokinetics: A Systematic Review of Population Pharmacokinetics

  2023cites this paper
• Influence of Vitamin K intake on INR and Anticoagulation in outpatients taking Warfarin

  2022cites this paper
• Nonlinear Machine Learning in Warfarin Dose Prediction: Insights from Contemporary Modelling Studies

  2022cites this paper
• Bleeding complications in patients on warfarin undergoing joint injection/aspiration: systematic review and meta-analysis

  2022cites this paper
• Evaluation of supervised machine learning algorithms in predicting the poor anticoagulation control and stable weekly doses of warfarin

  2022cites this paper
• Warfarin Dosing in Patients With CYP2C9*5 Variant Alleles

  2022cites this paper
• Influence of CYP2C9, VKORC1, and CYP4F2 Genetic Variants on Warfarin Dosage Needs in Saudi Patients

  2022cites this paper
• Translational pharmacogenetics: pharmacogenetically driven clinical decision making

  2021cites this paper
• Warfarin maintenance dose prediction for Chinese after heart valve replacement by a feedforward neural network with equal stratified sampling

  2021cites this paper
• Dose, dosage regimen, and dose adjustment in organ failure

  2021cites this paper
• Comparison of multivariate linear regression and a machine learning algorithm developed for prediction of precision warfarin dosing in a Korean population

  2021cites this paper
• Association between polymorphisms in microRNA seed region and warfarin stable dose

  2020cites this paper
• Profiles of patients on warfarin anticoagulation therapy in a leading tertiary referral hospital in Kenya; findings and implications for Kenya

  2020cites this paper
• Influence of genotype on warfarin dose requirements-a systematic review and meta-analysis

  2020cites this paper
• Moving Towards Ideal and Appropriate Models of Anticoagulation Management Service

  2020cites this paper
• Pharmacogenetic Warfarin Dosing Algorithm in the Russian Population

  2019cites this paper
• PHARMACOGENETIQUE DE L’ACENOCOUMAROL : LES GENES IMPLIQUES DANS LA VARIABILITE DE LA REPONSE ET PROPOSITION D’UN ALGORITHME PREDICTIF DE LA DOSE POUR LA POPULATION MAROCAINE

  2019cites this paper
• Pharmacogenomic phase transition from personalized medicine to patient-centric customized delivery

  2019cites this paper
• Pharmacology of Oral Anticoagulants

  2019cites this paper
• The Impact of CYP2C9 and VKORC1 Polymorphism in Patient’s Response to Warfarin and Acenocoumarol

  2019cites this paper
• A Comprehensive Review on Medication Used for Warfarin Reversal

  2019cites this paper
• Warfarin Dosing According to the Genotype-guided Algorithm is Most Beneficial in Patients With Atrial Fibrillation: A Randomized Parallel Group Trial

  2018cites this paper
• Wastewater-based epidemiology in low Human Development Index states: bias in consumption monitoring of illicit drugs

  2018cites this paper
• Genomic Variation and Pharmacokinetics in Old Age: A Quantitative Review of Age‐ vs. Genotype‐Related Differences

  2018cites this paper
• GENOMIC MEDICINE IN CARDIOVASCULAR DISORDERS

  2018cites this paper
• Oral disintegrating patient-tailored tablets of warfarin sodium produced by 3D printing

  2018cites this paper
• Effect of CYP2C9, VKORC1, CYP4F2, and GGCX gene variants and patient characteristics on acenocoumarol maintenance dose: Proposal for a dosing algorithm for Moroccan patients.

  2018cites this paper
• Clinical and genetic factors influencing acenocoumarol dosing: a cross-sectional study

  2018cites this paper
• Running title: Prediction Success Criteria for Pharmacokinetic Parameters Correspondence

  2017cites this paper
• Pharmacogenetic dosing of warfarin in the Han-Chinese population: a randomized trial.

  2017cites this paper
• Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin: Twelve-Week Post-treatment Follow-up

  2017cites this paper
• Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism

  2017cites this paper
• Warfarin Pharmacogenomics in Diverse Populations

  2017cites this paper
• Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin

  2016cites this paper
• Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients

  2016cites this paper
• Enantiomeric separation and quantitation of warfarin and its metabolites in human plasma by LC-MS/MS

  2016cites this paper
• Potential Social, Ethical, and Legal Issues Raised by the Development of Pharmacogenetics

  2016cites this paper
• Anticoagulothérapie à la warfarine : influence de l’apport alimentaire de vitamine K

  2016cites this paper
• Profile and anticoagulation outcomes of patients on warfarin therapy in an urban hospital in Cape Town, South Africa

  2016cites this paper
• Tiempo en rango terapéutico (TRT) en clínica de anticoagulación

  2016cites this paper
• A multi-factorial analysis of response to warfarin in a UK prospective cohort

  2016cites this paper
• Time in therapeutic range (TTR) in anticoagulation clinic Reports of adverse events and factors associated with low TTR

  2016cites this paper
• Genetic determinants of response and adverse effects following vitamin K antagonist oral anticoagulants

  2016cites this paper
• Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.

  2016cites this paper
• CYP4F2 (rs2108622) Gene Polymorphism Association with Age-Related Macular Degeneration

  2016cites this paper
• Artificial neural network-based pharmacogenomic algorithm for warfarin dose optimization.

  2016cites this paper
• Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome

  2015cites this paper
• Validation of warfarin pharmacogenetic algorithms in 586 Han Chinese patients.

  2015cites this paper
• Estimation and validation of acenocoumarol dosing algorithms in Bulgarian patients with cardiovascular diseases.

  2015cites this paper
• Pharmacogenetic-guided algorithms to estimate personalized dose or individual responses to anti-thrombotic drugs

  2015cites this paper
• Acenocoumarol Pharmacogenetic Dosing Algorithms and Their Application in Two Bulgarian Patients with Low Anticoagulant Requirements

  2015cites this paper
• Effect of VKORC 1-1639 G > A polymorphism on warfarin response in east of Turkey Türkiye

  2015cites this paper
• Chapter 2.1.4 – Translational Pharmacogenetics to Support Pharmacogenetically Driven Clinical Decision Making

  2015cites this paper
• High intra- and inter-individual variability of plasma vitamin K concentrations in patients with atrial fibrillation under warfarin therapy

  2015cites this paper
• Comparison of warfarin therapy clinical outcomes following implementation of an automated mobile phone-based critical laboratory value text alert system

  2014cites this paper
• Comorbidités relatives aux hémorragies gastro-intestinales chez les patients sous Anti-Vitamine K pour une Fibrillation auriculaire : étude de cohorte à l'Île de La Réunion en comparaison avec la France métropolitaine entre 2010 et 2012

  2014cites this paper
• Deciding on Success Criteria for Predictability of Pharmacokinetic Parameters from In Vitro Studies: An Analysis Based on In Vivo Observations

  2014cites this paper
• Resistance and sensibility to warfarin

  2014cites this paper
• Patient-reported compliance with thromboprophylaxis using an oral factor Xa inhibitor (rivaroxaban) following total hip and total knee arthroplasty.

  2014cites this paper
• Characterization of a novel CYP2C9 mutation (1009C>A) detected in a warfarin-sensitive patient.

  2014cites this paper
• Study Of Genetic And Pharmacokinetic Issues Related To Efficacy And Toxicity Of Warfarin In Pakistani Subjects

  2014cites this paper
• Erblichkeit in der Aktivität der Enzyme CYP2D6 und CYP2C9 sowie des Transporters OATP1B1 unter Berücksichtigung der bereits bekannten genetischen Varianten

  2014cites this paper
• Drug focus on warfarin—an anticoagulant medication

  2014cites this paper
• The Pharmacogenomics of Cytochrome P450s: From Molecular to Clinical Application

  2014cites this paper
• Genotype and risk of major bleeding during warfarin treatment.

  2014cites this paper
• Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism

  2014cites this paper
• Association between ABCG2 and ABCB1 genes and warfarin stability: a case-control study.

  2014cites this paper
• Validation of patient‐reported warfarin dose in a prospective incident cohort study

  2014cites this paper
• A study of correlation between CYP2C9 gene polymorphism and Warfarin maintenance dose in anticoagulant therapy among Han people in Yunnan of China

  2014cites this paper
• Microsoft Word-64447191-file00.docx

  2014influential citation
• Prediction of optimal warfarin maintenance dose using advanced artificial neural networks.

  2014cites this paper
• Polskie zalecenia dotyczące leczenia antagonistami witaminy K

  2013cites this paper
• Pharmacogenetics of warfarin: challenges and opportunities

  2013cites this paper
• which should help ultimately with working towards a stratifi ed medicines approach.

  2013cites this paper
• Impact of Genetic Factors (CYP2C9, VKORC1 and CYP4F2) on Warfarin Dose Requirement in the Turkish Population

  2013cites this paper
• Genetics of warfarin dosing--one polymorphism at a time.

  2013cites this paper
• Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P-450 CYP2C9 and 1639G>A of the VKORC1 gene; On acenocoumarol requirement in Moroccan patients.

  2013cites this paper
• The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population.

  2013cites this paper
• Pharmacogenetics of Oral Anticoagulants and Antiplatelets

  2013cites this paper
• Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature.

  2013cites this paper
• interindividual variability in the dose-anticoagulant effect of warfarin A polymorphism in the VKORC1 gene is associated with an

  2013cites this paper
• Quantitative Prediction of the Impact of Drug Interactions and Genetic Polymorphisms on Cytochrome P450 2C9 Substrate Exposure

  2013cites this paper
• Comparative evaluation of warfarin utilisation in two primary healthcare clinics in the Cape Town area

  2013cites this paper
• Hemostasis and Thrombosis

  2013cites this paper
• Warfarin Pharmacogenetics: New Life for an Old Drug.

  2013cites this paper
• Validation of a Proposed Warfarin Dosing Algorithm Based on the Genetic Make-Up of Egyptian Patients

  2013cites this paper
• Warfarin pharmacogenomics in children

  2013cites this paper
• The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.

  2012cites this paper
• Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers

  2012cites this paper
• A du gène VKORC 1 ; sur les besoins en acenocoumarol chez des patients marocains

  2012cites this paper
• Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cites this paper